Core Viewpoint - The introduction of the "Zeiss Next-Generation Robot All-Laser SMILE VISUMAX 800" at Ningbo Yinzhou Eye Hospital marks a significant advancement in refractive surgery, promising a faster, smarter, and safer experience for patients with myopia and astigmatism [1] Group 1: Advantages of VISUMAX 800 - The device completes key scanning steps in just 10 seconds, significantly reducing patient anxiety and minimizing external interference risks during the procedure [2] - It features intelligent tracking and automatic correction capabilities, allowing for precise adjustments even if the patient's eye moves slightly, enhancing visual quality post-surgery, especially for astigmatism patients [2] - The upgraded suction system reduces the incidence of complications by approximately 94%, and the precise control of laser energy minimizes corneal tissue damage, increasing patient confidence in the procedure [2] Group 2: Expert Insights and Hospital Commitment - The hospital's team, led by Dr. Huang Xu, emphasizes the benefits of the VISUMAX 800 in providing a shorter cooperation time during surgery, reducing psychological burden, and improving overall surgical experience [3] - The Ningbo Yinzhou Eye Hospital has a strong foundation in refractive surgery, having performed tens of thousands of procedures, and Dr. Huang has received official operational certification for the VISUMAX 800 [3] - The hospital aims to integrate advanced technology with clinical expertise to offer high-quality refractive services to local residents, ensuring they have access to international standards of care [5] Group 3: Technological Advancements Timeline - The hospital has progressively adopted cutting-edge technology, introducing VISUMAX equipment in 2021, advancing to the all-laser 3.0 era, and planning to implement the VISULYZE system in 2024 [4] - The introduction of VISUMAX 800 in 2025 is expected to revolutionize the refractive surgery experience, enabling a "10-second vision correction" era [4]

Group 1 - Refractive surgery is a surgical procedure that corrects vision by altering the eye's refractive system, primarily targeting myopia, hyperopia, and astigmatism [3] - The refractive surgery market is experiencing a new wave of transformation driven by advanced technologies such as precise femtosecond laser 4.0, all-light sculpting, and EVO+ICL, which are expected to significantly increase the average transaction price [1][2] - The domestic refractive surgery market was nearly 35 billion yuan in 2022, with a low penetration rate of 0.7 surgeries per thousand people in 2021, indicating substantial room for growth compared to developed countries like the US, which had 2.6 surgeries per thousand people [1][30] Group 2 - The refractive surgery sector is a core business in private ophthalmology, contributing significantly to profit growth due to its large market size and strong profitability [1][41] - The introduction of new technologies and equipment is anticipated to stimulate demand, leading to a potential price increase in refractive surgeries, alongside a recovery in consumer expectations [1][41] - Companies such as Aier Eye Hospital, Huaxia Eye Hospital, and others are recommended for attention due to their positioning in the growing refractive surgery market [1][41] Group 3 - The evolution of refractive surgery equipment has been steady, with significant advancements occurring approximately every decade, culminating in the upcoming launch of the VISUMAX 800 and SMILE pro in 2025 [8][12] - The new femtosecond laser 4.0 technology offers enhanced precision and customization, with a higher average transaction price compared to previous versions [9][10] - The all-light sculpting technique utilizes a 3D model of the eye and AI algorithms for personalized treatment, marking a significant advancement in refractive surgery [14] Group 4 - The refractive surgery market is expected to see a dual impact on performance and valuation due to technological upgrades and the release of pent-up demand [1][41] - The average age of patients undergoing refractive surgery in China is significantly lower than in Europe, indicating a different demographic focus and potential for market expansion [37][38] - The introduction of new materials like EVO+ICL (V5) and Longjing PR is expected to enhance visual quality and safety for patients, further driving market growth [21][27]